Johnson & Johnson beat expectations for quarterly earnings and raised its dividend payouts to shareholders on Tuesday, while reporting $100 million in sales of its COVID-19 vaccine, whose use was paused by U.S. regulators last week. The company, which has previously said the vaccine will be available on a not-for-profit basis until the end of the pandemic, also tightened its forecast for adjusted profit this year, suggesting it was largely performing as previously expected. Use of the company’s vaccine was temporarily halted by U.S. regulators as they investigate reports of blood clots in six women, prompting a similar pause in South Africa and leading to a delay in rollout in Europe. The United States is also reviewing a handful of potential cases of severe side effects in addition to those that led to the pause. J&J is aiming to deliver 100 million doses of the vaccine to the United States …